DK0815112T3 - Fremgangsmåde til isolering af galanthamin - Google Patents

Fremgangsmåde til isolering af galanthamin

Info

Publication number
DK0815112T3
DK0815112T3 DK96907470T DK96907470T DK0815112T3 DK 0815112 T3 DK0815112 T3 DK 0815112T3 DK 96907470 T DK96907470 T DK 96907470T DK 96907470 T DK96907470 T DK 96907470T DK 0815112 T3 DK0815112 T3 DK 0815112T3
Authority
DK
Denmark
Prior art keywords
galanthamine
isolating
isolating galanthamine
extraction
instance
Prior art date
Application number
DK96907470T
Other languages
Danish (da)
English (en)
Inventor
Thomas Hille
Hans-Rainer Hoffmann
Mirko Kreh
Rudolf Matusch
Original Assignee
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohmann Therapie Syst Lts filed Critical Lohmann Therapie Syst Lts
Application granted granted Critical
Publication of DK0815112T3 publication Critical patent/DK0815112T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Extraction Or Liquid Replacement (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK96907470T 1995-03-17 1996-03-14 Fremgangsmåde til isolering af galanthamin DK0815112T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19509663A DE19509663A1 (de) 1995-03-17 1995-03-17 Verfahren zur Isolierung von Galanthamin
PCT/EP1996/001094 WO1996029332A1 (fr) 1995-03-17 1996-03-14 Procede d'isolation de galanthamine

Publications (1)

Publication Number Publication Date
DK0815112T3 true DK0815112T3 (da) 2001-11-12

Family

ID=7756925

Family Applications (2)

Application Number Title Priority Date Filing Date
DK96907470T DK0815112T3 (da) 1995-03-17 1996-03-14 Fremgangsmåde til isolering af galanthamin
DK01100944T DK1095656T3 (da) 1995-03-17 1996-03-14 Farmaceutiske sammensætninger med cholinesterasehæmmeren galanthamin

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK01100944T DK1095656T3 (da) 1995-03-17 1996-03-14 Farmaceutiske sammensætninger med cholinesterasehæmmeren galanthamin

Country Status (23)

Country Link
US (5) US5877172A (fr)
EP (2) EP1095656B1 (fr)
JP (1) JP3863180B2 (fr)
KR (1) KR100427093B1 (fr)
CN (1) CN1088460C (fr)
AT (2) ATE203993T1 (fr)
AU (1) AU707203B2 (fr)
CA (1) CA2215351C (fr)
CZ (1) CZ294722B6 (fr)
DE (3) DE19509663A1 (fr)
DK (2) DK0815112T3 (fr)
ES (2) ES2206356T3 (fr)
HU (1) HU225267B1 (fr)
IL (1) IL117371A (fr)
MY (1) MY114698A (fr)
NO (1) NO316380B1 (fr)
NZ (1) NZ304008A (fr)
PL (1) PL184238B1 (fr)
PT (2) PT1095656E (fr)
SI (1) SI1095656T1 (fr)
SK (1) SK283861B6 (fr)
WO (1) WO1996029332A1 (fr)
ZA (1) ZA962140B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19509663A1 (de) 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
AT402691B (de) * 1996-01-26 1997-07-25 Sanochemia Ltd Verwendung von galanthamin zum herstellen von arzneimitteln zur behandlung von trisomie 21 oder verwandter trisomie-syndrome
US8603546B2 (en) * 1999-01-11 2013-12-10 Herbaceuticals Inc. Herbal supplement for increased muscle strength and endurance for athletes
EP1150695B1 (fr) * 1999-01-11 2007-02-28 Atanas Russinov Djananov Complement alimentaire vegetal servant a ameliorer la resistance musculaire et l'endurance d'athletes
DE19906974C2 (de) * 1999-02-19 2003-10-09 Lohmann Therapie Syst Lts Verwendung von Desoxypeganin zur Behandlung des Alkoholismus
DE19906975B4 (de) * 1999-02-19 2004-04-15 Lts Lohmann Therapie-Systeme Ag Arzneiform zur Behandlung von Alzheimer'scher Demenz
GB9909469D0 (en) * 1999-04-23 1999-06-23 Wilkinson John A Insectidal composition
US6426097B2 (en) * 2000-01-28 2002-07-30 Herbaceuticals Inc. Herbal supplement for cognitive related impairment due to estrogen loss
CA2310926C (fr) * 2000-04-03 2002-10-15 Janssen Pharmaceutica N.V. Utilisation de la galantamine pour le traitement du comportement neuropsychiatrique associe a la maladie d'alzheimer
DE10119862A1 (de) * 2001-04-24 2002-11-07 Hf Arzneimittelforsch Gmbh Verwendung von Galanthamin zur Behandlung von Krankheitserscheinungen des zentralen Nervensystems aufgrund von Intoxikationen mit psychotropen Substanzen
DE10129265A1 (de) * 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
DE10134038A1 (de) * 2001-07-12 2003-02-06 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit
ATE459877T1 (de) * 2001-12-10 2010-03-15 Univ Washington Diagnostikum für die frühe phase von morbus alzheimer
US20040067934A1 (en) * 2002-10-03 2004-04-08 Parys Wim Louis Julien Use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
AU2004216360B2 (en) * 2003-02-27 2009-09-17 Eisai R & D Management Co., Ltd. Pharmaceutical composition for treatment of drug dependence
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
US20050191349A1 (en) * 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations
US20050142193A1 (en) * 2003-12-31 2005-06-30 Lijuan Tang Galantamine formulations
WO2006013546A2 (fr) * 2004-07-28 2006-02-09 Ranbaxy Laboratories Limited Procede de preparation de galantamine pure
FR2879599B1 (fr) * 2004-12-16 2007-03-23 Centre Nat Rech Scient Cnrse Utilisation de la chromatographie de partage centrifuge pour la purification de la galanthamine
ITMI20042413A1 (it) * 2004-12-17 2005-03-17 Indena Spa Processo per la preparazione di galantamina bromidrato
KR20070119641A (ko) * 2005-03-17 2007-12-20 아이박스 파마슈티컬스 에스.알.오. 생체 물질로부터 갈란타민을 단리하는 방법
ATE478659T1 (de) * 2005-05-13 2010-09-15 Alza Corp Mehrlagiges arzneimittelausbringsystem mit sperre gegen reservoirmaterialfluss
CN1307180C (zh) * 2005-05-24 2007-03-28 天津大学 从石蒜或雪花莲属原料中提取加兰他敏的方法
WO2007035941A2 (fr) * 2005-09-23 2007-03-29 Alza Corporation Systeme d'administration transdermique de galantamine
US7446352B2 (en) * 2006-03-09 2008-11-04 Tela Innovations, Inc. Dynamic array architecture
JP2009084281A (ja) 2007-09-18 2009-04-23 Ethicon Endo Surgery Inc 術後イレウスの低減のための方法
EP2330910B1 (fr) * 2008-09-11 2017-08-16 Israeli Biotechnology Research Ltd. Utilisation cosmétique des extraits du bulbe de leucojum
US8247405B2 (en) * 2008-12-10 2012-08-21 Conopco, Inc. Skin lightening compositions with acetylcholinesterase inhibitors
CN101602767B (zh) * 2009-05-26 2012-01-11 苏州派腾生物医药科技有限公司 一种加兰他敏的制备方法
DE102009040381A1 (de) 2009-09-07 2011-03-17 Kallimopoulos, Thomas, Dr. Verfahren zur Isolierung von Alkaloiden aus Pflanzen
CN101787028B (zh) * 2010-01-12 2012-01-04 恩施清江生物工程有限公司 一种从忽地笑中提取加兰他敏的方法
CN102050826B (zh) * 2010-12-21 2012-11-14 浙江工业大学 一种分离加兰他敏的方法
BG67337B1 (bg) 2018-05-23 2021-06-15 Софарма Ад Метод за получаване на пречистен галантамин хидробромид
CN117717558A (zh) * 2023-12-06 2024-03-19 艾威药业(珠海)有限公司 加兰他敏及其药学上可接受的盐在制备治疗眼部疾病的药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1193061B (de) * 1961-12-20 1965-05-20 Vni Chimiko Pharmazewtitschesk Verfahren zur Gewinnung von Galanthamin-hydrobromid aus Pflanzen der Familie der Amaryllidaceen
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5519017A (en) * 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
WO1992020327A1 (fr) * 1991-05-14 1992-11-26 Ernir Snorrason Traitement des etats de fatigue a l'aide d'inhibiteurs de cholinesterase
DE4301782C1 (de) * 1993-01-23 1994-08-25 Lohmann Therapie Syst Lts Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
DE4301783C1 (de) 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
US5428159A (en) * 1994-04-08 1995-06-27 Ciba-Geigy Corporation Method of manufacture of (-)-galanthamine in high yield and purity substantially free of epigalanthamine
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin

Also Published As

Publication number Publication date
ATE203993T1 (de) 2001-08-15
CA2215351C (fr) 2005-01-11
HUP9802234A2 (hu) 1999-02-01
CN1088460C (zh) 2002-07-31
SK123597A3 (en) 1998-02-04
NO316380B1 (no) 2004-01-19
MX9707015A (es) 1997-11-29
EP1095656A2 (fr) 2001-05-02
JP3863180B2 (ja) 2006-12-27
US6335328B2 (en) 2002-01-01
NO974119L (no) 1997-09-08
ZA962140B (en) 1996-09-16
NO974119D0 (no) 1997-09-08
SK283861B6 (sk) 2004-03-02
CZ283597A3 (en) 1997-12-17
KR100427093B1 (ko) 2004-07-31
WO1996029332A1 (fr) 1996-09-26
HUP9802234A3 (en) 2000-03-28
PL322463A1 (en) 1998-02-02
DE59610680D1 (de) 2003-09-25
EP0815112A1 (fr) 1998-01-07
KR19980703067A (ko) 1998-09-05
AU5108896A (en) 1996-10-08
US20030012831A1 (en) 2003-01-16
CA2215351A1 (fr) 1996-09-26
DK1095656T3 (da) 2003-12-08
IL117371A0 (en) 1996-07-23
PT1095656E (pt) 2004-01-30
ES2206356T3 (es) 2004-05-16
AU707203B2 (en) 1999-07-08
MY114698A (en) 2002-12-31
US6573376B2 (en) 2003-06-03
PL184238B1 (pl) 2002-09-30
EP1095656A3 (fr) 2001-05-16
US20010001100A1 (en) 2001-05-10
PT815112E (pt) 2002-01-30
IL117371A (en) 2000-01-31
EP1095656B1 (fr) 2003-08-20
HU225267B1 (en) 2006-08-28
US20020028802A1 (en) 2002-03-07
US6617452B2 (en) 2003-09-09
ATE247473T1 (de) 2003-09-15
ES2162035T3 (es) 2001-12-16
DE19509663A1 (de) 1996-09-19
NZ304008A (en) 1998-09-24
CN1178533A (zh) 1998-04-08
SI1095656T1 (en) 2004-02-29
EP0815112B1 (fr) 2001-08-08
DE59607450D1 (de) 2001-09-13
JPH11505519A (ja) 1999-05-21
US6194404B1 (en) 2001-02-27
US5877172A (en) 1999-03-02
CZ294722B6 (cs) 2005-03-16

Similar Documents

Publication Publication Date Title
DK0815112T3 (da) Fremgangsmåde til isolering af galanthamin
DK0476704T3 (da) Fremgangsmåde til føring af procesgas i et apparat samt et apparat til udøvelse af fremgangsmåden
DK0616821T3 (da) Ekstraktion af duftstoffer
DK0413019T3 (da) Syntetiske plantegener og fremgangsmåde til fremstilling af disse
DK117892A (da) Fremgangsmåde og anlæg til fremstilling af chokoladeartikler
DE69619606D1 (de) Merkmalermittlungsanlage
DK1142485T3 (da) Fremgangsmåde til forbedring af oplöseligheden af planteproteiner
DK0862865T3 (da) Behandling af tobak
EP0746038A3 (fr) Transistor PNP vertical isolé et sa méthode de fabrication
ZA949180B (en) Hepatoblasts and method of isolating same
DK0463664T3 (da) Fremgangsmåde til behandling af en underjordisk formation
DK0525027T3 (da) Fremgangsmåde til udvinding af naturgas i form af en normalt flydende carbonholdig forbindelse
NO177161C (no) Anordning ved gjenvinning av overskuddsgass i et olje/gassbehandlingsanlegg
EP0529413A3 (en) Method of separating organic solvents
NO940747D0 (no) Fremgangsmåte for gjenbruk av vannholdig plantemateriale
CS689890A3 (en) Massage ointment containing plant extracts and process for preparingthereof
PL289404A1 (en) Method of isolating alkaloids as individual compounds or in groups from materials of plant origin
DK74396A (da) Fremgangsmåde til fremstilling af et skilt og skilt fremstillet ifølge fremgangsmåden samt en genstand med et sådane skilt
HUT70793A (en) Process for testing imporosity of reservoirs sunk into soil
PL301324A1 (en) Method of utilizing flotation process wastes
PL280407A1 (en) Method of obtaining purified plant lecithin
NO932548D0 (no) Mikrobiologisk metode for oekt oljeutvinning
HUT73638A (en) Process for extracting organic components of natural water and producing pharmaceutical compositions comprising this extract
UA24959C2 (uk) Спосіб збагачуваhhя вугілля у важких суспеhзіях з використаhhям породhої суспеhзії
UA27960C2 (uk) Спосіб вилучення германію із надсмольної води коксохімічного виробництва